Identifying the target of a drug candidate (also known as target deconvolution) remains a time-consuming and challenging phase of drug development for the pharmaceutical industry.
Present conventional target deconvolution methods are unable to take account of the drug’s physiological environment, resulting in a biased ternary structure and the loss of the quaternary structure of the therapeutic target.
This lost information is not only crucial for elucidating the biological mechanism of a disease but also beneficial for rational drug design, efficient structure-activity relationship studies, and the investigation of aspects pertaining to target-specific toxicity and side effects.
Inoviem Scientific has developed an original heterogeneous assembly method to identify exhaustively all of the proteins (together with their native structure) involved in drug target interaction. This information allows us to understand the biological mechanism of a disease, a drug candidate’s mechanism of action, and the origin of side effects.
We use this information to design or re-design drug candidates accordingly.
Since our technology uses crude human tissue, we identify therapeutic targets within their natural environment, and thus with all the post-translational modifications they encounter physiologically.
Our technology also allows us to identify relevant biomarkers related to a disease or associated with a drug candidate.